Skip to main content
SpringerLink
Log in

Activation of peroxisome proliferator-activated receptors α and γ1 inhibits human smooth muscle cell proliferation

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Atherosclerotic lesions occur as a result of excess lipid deposition within the vascular tissues. The peroxisome proliferator-activated receptors (PPARs) present in adipose and hepatic tissues have been shown to promote fatty acid oxidation and lipid storage. An immunohistochemical assessment of PPARα and PPARγ revealed both proteins were also present in the medial and intimal layers of human arteries, predominately in regions containing smooth muscle cells. In agreement with this observation, smooth muscle cells isolated from these vessels were found by RT-PCR to express both PPARα and PPARγ1. The functionality of these receptors was tested with selective PPAR agonists. Mitogenic stimulation of smooth muscle cell proliferation was blocked by 15d-PGJ2, a PPARγ agonist, as well as by WY14643, a PPARα agonist. These data indicate PPAR activation by selective agonists could influence lesion progression directly, as well as indirectly through reductions in serum lipoprotein and triglyceride levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Torra IP, Chinetti G, Duval C, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors: From transcriptional control to clinical practice. Curr Opin Lipidol 12: 245-254, 2001

    Google Scholar 

  2. Qi C, Zhu Y, Reddy JK: Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys 32: 187-204, 2000

    Google Scholar 

  3. Clarke SD: Polyunsaturated fatty acid regulation of gene transcription: A mechanism to improve energy balance and insulin resistance. Br J Nutr 83(suppl 1): S59-S66, 2000

    Google Scholar 

  4. Schoonjans K, Staels B, Auwerx J: The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1302: 93-109, 1996

    Google Scholar 

  5. Stacls B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393: 790-793, 1998

    Google Scholar 

  6. Inoue I, Shino K, Noji S, Awata T, Katayama S: Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 246: 370-374, 1998

    Google Scholar 

  7. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B: Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem 273: 25573-25580, 1998

    Google Scholar 

  8. Marx N, Mackman N, Schonbeck U, Yilmaz N, Hombach VV, Libby P, Plutzky J: PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 103: 213-219, 2001

    Google Scholar 

  9. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J: PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19: 546-551, 1999

    Google Scholar 

  10. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J: PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99: 3125-3131, 1999

    Google Scholar 

  11. Chinetti G, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors with functions in the vascular wall. Z Kardiol 90(suppl 3): 125-132, 2001

    Google Scholar 

  12. Miwa Y, Sasaguri T, Inoue H, Taba Y, Ishida A, Abumiya T: 15-Deoxydelta(12,14)-prostaglandin J(2) induces G(1) arrest and differentiation marker expression in vascular smooth muscle cells. Mol Pharmacol 58: 837-844, 2000

    Google Scholar 

  13. Gouni-Berthold I, Berthold HK, Weber AA, Seul C, Vetter H, Sachinidis A: Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth. Exp Clin Endocrinol Diabetes 109: 203-209, 2001

    Google Scholar 

  14. Del Rizzo DF, Yurkova N, Moon MC, Litchie B, Zahradka P: Platelet-derived growth factor-induced expression of c-fos in human vascular smooth muscle cells: Implications for longterm graft patency. Ann Thorac Surg 74: 90-95, 2002

    Google Scholar 

  15. Zahradka P, Elliot T, Hovland K, Larson DE, Saward L: Repression of histone gene transcription in quiescent 3T6 fibroblasts. Eur J Biochem 217: 683-690, 1993

    Google Scholar 

  16. Zahradka P, Harris KD, Triggs-Raine B, Lamontagne G, Leblanc N: PCR-based analysis of voltage-gated K+ channels in vascular smooth muscle. Mol Cell Biochem 145: 39-44, 1995

    Google Scholar 

  17. Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83: 1097-1103, 1998

    Google Scholar 

  18. Benson S, Wu J, Padmanabhan S, Kurtz TW, Pershadsingh HA: Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: Inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone. Am J Hypertens 13: 74-82, 2000

    Google Scholar 

  19. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA: Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 101: 1311-1318, 2000

    Google Scholar 

  20. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: 410-418, 1999

    Google Scholar 

  21. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK: Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106: 523-531, 2000

    Google Scholar 

  22. Takagi T, Akasaka T, Yamamuro A, Honda Y, Hozumi T, Morioka S, Yoshida K: Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: A serial intravascular ultrasound study. J Am Coll Cardiol 36: 1529-1535, 2000

    Google Scholar 

  23. Elangbam CS, Tyler RD, Lightfoot RM: Peroxisome proliferator-activated receptors in atherosclerosis and inflammation — an update. Toxicol Pathol 29: 224-231, 2001

    Google Scholar 

  24. Zhang X, Wang JM, Gong WH, Mukaida N, Young HA: Differential regulation of chemokine gene expression by 15-deoxy-delta 12,14 prostaglandin J2. J Immunol 166: 7104-7111, 2001

    Google Scholar 

  25. Chiba Y, Ogita T, Ando K, Fujita T: PPARgamma ligands inhibit TNF-alpha-induced LOX-1 expression in cultured endothelial cells. Biochem Biophys Res Commun 286: 541-546, 2001

    Google Scholar 

  26. Palakurthi SS, Aktas II, Grubissich LM, Mortensen RM, Halperin JA: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 61: 6213-6218, 2001

    Google Scholar 

  27. Maggi LB Jr, Sadeghi H, Weigand C, Scarim AL, Heitmeier MR, Corbett JA: Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: Evidence for heat shock-dependent and-independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 49: 346-355, 2000

    Google Scholar 

  28. Betz E, Quack G: Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosis. Vasa 19: 157-160, 1990

    Google Scholar 

  29. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7: 53-58, 2001

    Google Scholar 

  30. Jones DC, Ding X, Daynes RA: Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem 277: 6838-6845, 2002

    Google Scholar 

  31. Diep QN, Touyz RM, Schiffrin EL: Docosahexaenoic acid, a peroxisome proliferator-activated receptor-alpha ligand, induces apoptosis in vascular smooth muscle cells by stimulation of p38 mitogen-activated protein kinase. Hypertension 36: 851-855, 2000

    Google Scholar 

  32. Ma X, Stoffregen DA, Wheelock GD, Rininger JA, Babish JG: Discordant hepatic expression of the cell division control enzyme p34cdc2 kinase, proliferating cell nuclear antigen, p53 tumor suppressor protein, and p21 Wafl cyclin-dependent kinase inhibitory protein after WY14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid) dosing to rats. Mol Pharmacol 51: 69-78, 1997

    Google Scholar 

  33. Zahradka P, Werner JP, Buhay S, Litchie B, Thomas S: NF-κB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. J Mol Cell Cardiol 34: 1609-1621, 2002

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre and Department of Phsiology, University of Manitoba, Winnipeg, Canada

    Peter Zahradka, Natalia Yurkova & Brenda Litchie

  2. Institute of Cardiovascular Sciences, St. Boniface General Hospital Research Centre, Departments of Surgery and Physiology, University of Manitoba, Winnipeg, Canada

    Michael C. Moon

  3. Department of Surgery, University of Manitoba, Winnipeg, Canada

    Dario F. Del Rizzo

  4. Department of Human Nutritional Sciences, University of Manitoba, Winnipeg, Canada

    Carla G. Taylor

Authors
  1. Peter Zahradka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalia Yurkova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Brenda Litchie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael C. Moon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dario F. Del Rizzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carla G. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zahradka, P., Yurkova, N., Litchie, B. et al. Activation of peroxisome proliferator-activated receptors α and γ1 inhibits human smooth muscle cell proliferation. Mol Cell Biochem 246, 105–110 (2003). https://doi.org/10.1023/A:1023424500160

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1023424500160

Search

Navigation